Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 29
 
Share:
Send email
Share:
Original paper

Real-world treatment patterns of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer

Barbara Radecka
1, 2
,
Bogdan Żurawski
3
,
Aleksandra Łacko
4, 5
,
Aleksandra Anna Grela-Wojewoda
6
,
Karolina Wieruszewska-Kowalczyk
7
,
Elżbieta Senkus-Konefka
8, 9

  1. Department of Oncology, Institute of Medical Sciences, University of Opole, Opole, Poland
  2. Department of Clinical Oncology, Tadeusz Koszarowski Cancer Center, Opole, Poland
  3. Department of Outpatient Chemotherapy, Professor Franciszek Łukaszczyk Oncology Center, Bydgoszcz, Poland
  4. Division of Solid Tumour Systemic Therapy, Department of Oncology, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland
  5. Department of Clinical Oncology, Brest Cancer, Lower Silesion Oncology, Pulmunology and Hematology Centre, Wrocław, Poland
  6. Department of Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków Branch, Kraków, Poland
  7. Pfizer Polska sp. z o. o., Warszawa, Poland
  8. Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
  9. Breast Unit, University Clinical Center, Gdańsk, Poland
Contemp Oncol (Pozn) 2025; 29 (4): 370–376
DOI: https://doi.org/10.5114/wo.2025.156076
Online publish date: 2025/11/11
Article file
- Real-world treatment.pdf  [0.09 MB]
Get citation
 
PlumX metrics:
 
1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022; 66: 15-23.
2. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021; 32: 1475-1495.
3. Female Breast Cancer Subtypes – Cancer Stat Facts. Surveillance, Epidemiology, and End Results Program. United States of America, Bethesda, MD: National Cancer Institute 2024.
4. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925-1936.
5. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022; 386: 942-950.
6. Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2– advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 2024; 35: 718-727.
7. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623-1649.
8. Network NCC. NCCN Clinical practice guidelines in oncology. Breast cancer (NCCN Guidelines) Version 2.2020.: NCCN.
9. De Wilde RL, Devassy R, Torres-de la Roche LA, Krentel H, Tica V, Cezar C. Guidance and standards for breast cancer care in Europe. J Obstet Gynaecol India 2020; 70: 330-336.
10. Hofmarcher T, Berchet C, Dedet G. Access to oncology medicines in EU and OECD countries. OECD Health Working Papers. Paris: Organisation for Economic Co-operation and Development 2024.
11. Ziobro M, Grela-Wojewoda A. Shifting treatment paradigms: improvements in HR-positive, HER-2- negative breast cancer care in Poland from a clinical perspective. Biomedicines 2023; 11: 510.
12. Jassem J, Krzakowski M. Breast cancer. Oncol Clin Pract 2018; 14: 171-215.
13. Didkowska J, Wojciechowska U, Michalek IM, Caetano Dos San- tos FL. Cancer incidence and mortality in Poland in 2019. Sci Rep 2022; 12: 10875.
14. Caetano Dos Santos FL, Michalek IM, Wojciechowska U, Dzidkowska J. Changes in the survival of patients with breast cancer: Poland, 2000–2019. Breast Cancer Res Treat 2023; 197: 623-631.
15. Jassem J, Krzakowski M, Bobek-Billewicz B, Duchnowska R, Jeziorski A, Olszewski W, et al. Breast cancer. Oncol Clin Pract 2020; 16: 207-260.
16. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Breast cancer (NCCN Guidelines) Version 1.2025.: NCCN.
17. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Poland Edition. Breast cancer (NCCN Guidelines) Version 4.2024.: NCCN.
18. Luo C, Yu K, Luo X, Lian T, Liu X, Xu W, et al. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/ HER2– advanced breast cancer: a phase III RCTs based meta-analysis. BMC Cancer 2024; 24: 1031.
19. Caldeira R, Scazafave M. Real-world treatment patterns for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Europe and the United States. Oncol Ther 2016; 4: 189-197.
20. Davie A, Cuyun Carter G, Rider A, Bailey A, Lewis K, Price G, et al. Real-world clinical profile, treatment patterns and patient-repor-ted outcomes in a subset of HR+/HER2– advanced breast cancer patients with poor prognostic factors: data from an international study. ESMO Open 2021; 6: 100226.
21. Meegdes M, Geurts SME, Erdkamp FLG, Wouter Dercksen M, Vriens BEPJ, Aaldering KNA, et al. Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2– metastatic breast cancer: an observational study of the SONABRE Registry. Lancet Reg Health Eur 2023; 26: 100573.
22. Almekinders CAM, Lin L, Beijnen JH, Sonke GS. Treatment sequen-ces and survival outcomes in advanced HR + HER2– breast cancer patients: a real-world cohort. Breast Cancer Res Treat 2024; 210: 115-124.
23. Sonke GS, Nijhof AVO, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). J Clin Oncol 2023; 41: LBA1000-LBA1000.
24. Duchnowska R, Soter K, Smok-Kalwat J, Grela-Wojewoda A, Winsko-Szczęsnowicz K, Pogoda K, et al. Real-world treatment outcomes in patients with HR+ HER2– advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy. J Clin Oncol 2024; 42: 1067-1067.
25. Geisler J, Karihtala P, Tuxen M, Valachis A, Holm B. Current treatment landscape of HR+/HER2– advanced breast cancer in the Nordics: a modified Delphi study. Acta Oncol 2023; 62: 1680-1688.
26. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425-439.
27. Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35: 2875-2884.
28. Slamon DJ, Neven P, Chia S, Fasching PA, de Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472.
29. Wysocki PJ. Wise and skillful utilization of contemporary endocrine therapies for the treatment of ER+/HER2 – advanced breast cancer. Oncol Clin Pract 2024; 20: 291-301.
30. Daily K, Douglas E, Romitti PA, Thomas A. Epidemiology of de novo metastatic breast cancer. Clinical Breast Cancer 2021; 21: 302-308.
31. Benitez Fuentes JD, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, et al. Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncology 2024; 10: 71-78.
32. Data on the implementation of preventive programs as of September 1, 2021. Warsaw: National Health Fund 2021.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.